医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

DxTerity’s REDI-Dx Wins 2013 NCT CBRNe Product of the Year Award

2013年12月21日 AM12:25
このエントリーをはてなブックマークに追加


 

LOS ANGELES

DxTerity Diagnostics announced that REDI-Dx™, the company’s blood-based gene expression test for estimating individualized levels of radiation exposure,* was named the 2013 NCT CBRNe Product of the Year. The award was presented at the NCT CBRNe (Non-Conventional Threat Chemical Biological Radiological Nuclear explosion) Asia conference in Kuala Lumpur, Malaysia. REDI-Dx was unanimously selected by the contest jury because “it has a clear end-user benefit, economic efficiency and an excellent match between requirements and the offered solution,” according to Ilja Bonsen, founder and Managing Director of IB Consultancy, an independent defense and security firm specializing in non-conventional threats. “Against the background of mass scale incidents like Fukushima, it permits fast analysis and treatment of victims on the basis of low-cost testing,” according to several members of the award committee.

REDI-Dx is a molecular test designed to estimate an individual’s level of radiation exposure by measuring the relative expression of a panel of radiation-sensitive genes in a blood sample that is collected by either fingerstick or venipuncture. The test represents a significant advance in coordinating an organized response to a nuclear incident by providing emergency responders with rapid, patient-specific information about levels of absorbed ionizing radiation. REDI-Dx was developed as part of an ongoing collaboration between DxTerity Diagnostics and Duke University Medical Center, with funding from the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA).

According to Bob Terbrueggen, CEO of DxTerity Diagnostics, “We are excited to receive this award. It recognizes the importance of providing emergency responders with simple biodosimetry tools for testing individuals following a mass scale nuclear incident.”

About DxTerity

DxTerity is a molecular diagnostic company and clinical laboratory based in Rancho Dominguez, CA, that is making genomic testing a routine part of medical care. DxTerity has developed the DxDirect genomic platform that enables simple, fast, and affordable measurement of genomic biomarkers from a single drop of blood.

DxTerity, DxDirect, and REDI-Dx are registered trademarks of DxTerity Diagnostics, Inc.

*REDI-Dx is for Research Use Only. Not for use in diagnostic procedures.

CONTACT

DxTerity Diagnostics Inc.
Phillip Chu, 310-537-7857
info@dxterity.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Celltrion Develops Tailored Neutralising Antibody Cocktail Treatment with CT-P59 to Tackle COVID-19 Variant Spread Using Its Antibody Development Platform
  • Huami Corp Invests $5 Million in Hyperfine Research D Round to Support Accelerated Application of Disruptive MRI Technology
  • COVID WHO Investigation: A Smoke Screen for China, says AHF
  • New Frontier Health Corporation Announces Receipt of Clarification to Preliminary Non-Binding “Going Private” Proposal
  • 美国项目管理协会发布的《 2021年大趋势》聚焦项目将如何平衡新兴的颠覆力量